Skip to main content

Terns Pharmaceuticals, Inc. (TERN)

NASDAQ: TERN · IEX Real-Time Price · USD
9.36 -0.26 (-2.70%)
Oct 22, 2021 4:00 PM EDT - Market closed
Market Cap235.22M
Revenue (ttm)n/a
Net Income (ttm)n/a
Shares Out25.11M
EPS (ttm)-3.39
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume39,627
Open9.63
Previous Close9.62
Day's Range9.13 - 9.57
52-Week Range6.92 - 28.36
Betan/a
AnalystsBuy
Price Target20.00 (+113.7%)
Est. Earnings DateNov 11, 2021

About TERN

Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis (NASH) and other chronic liver diseases. It develops TERN-101, a liver-distributed and non-bile acid farnesoid X receptor agonist, which is in Phase IIa clinical trial for the treatment of NASH; and TERN-201, a vascular adhesion protein-1 inhibitor that is in Phase I clinical trial for the treatment of NASH. The company also develops TERN-501, a thyroi...

IndustryBiotechnology
IPO DateFeb 5, 2021
Employees30
Stock ExchangeNASDAQ
Ticker SymbolTERN
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 3 analysts, the average rating for TERN stock is "Buy." The 12-month stock price forecast is 20.00, which is an increase of 113.68% from the latest price.

Price Target
$20.00
(113.68% upside)
Analyst Consensus: Buy

News

Terns Pharmaceuticals to Present Positive Clinical Data on NASH Programs at AASLD The Liver Meeting® Digital Experien...

FOSTER CITY, Calif., Oct. 18, 2021 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-m...

5 days ago - GlobeNewsWire

Terns Pharmaceuticals to Present at H.C. Wainwright 5th Annual NASH Investor Conference

FOSTER CITY, Calif., Oct. 05, 2021 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-m...

2 weeks ago - GlobeNewsWire

Terns Appoints Veteran Biopharmaceutical Executive Ann E. Taylor, M.D.

FOSTER CITY, Calif., Sept. 28, 2021 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-...

3 weeks ago - GlobeNewsWire

Terns Completes Part 1 Enrollment of AVIATION Phase 1b NASH Clinical Trial of VAP-1 Inhibitor TERN-201

-  TERN-201 is a highly selective VAP-1 inhibitor intended to address chronic liver inflammation and fibrosis in NASH

1 month ago - GlobeNewsWire

Terns Pharmaceuticals to Present at Upcoming Investor Conferences

FOSTER CITY, Calif., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-...

1 month ago - GlobeNewsWire

Terns Pharmaceuticals Reports Second Quarter 2021 Financial Results and Corporate Highlights

FOSTER CITY, Calif., Aug. 16, 2021 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-m...

2 months ago - GlobeNewsWire

Terns Announces Initiation of Patient Dosing in AVIATION Phase 1b NASH Clinical Trial of VAP-1 Inhibitor TERN-201

FOSTER CITY, Calif., June 24, 2021 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-m...

3 months ago - GlobeNewsWire

Terns Shares Drop After Mixed Results From Mid-Stage NASH Trial With FXR Agonist

Terns Pharmaceuticals Inc (NASDAQ: TERN) reported top-line results from the Phase 2a LIFT trial of TERN-101, a liver-distributed farnesoid X receptor (FXR) agonist for the treatment of patients with non...

4 months ago - Benzinga

Terns Reports Positive Top-line Results from Phase 2a LIFT Study of FXR Agonist TERN-101 in Patients with NASH

First FXR agonist trial to demonstrate no discontinuations due to AEs, including pruritus, and both a differentiated pruritus and lipid profile in patients with NASH

4 months ago - GlobeNewsWire

Terns Pharmaceuticals to Host Conference Call to Discuss Top-line Results from Phase 2a LIFT Study of TERN-101 for Tr...

FOSTER CITY, Calif., June 13, 2021 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-m...

4 months ago - GlobeNewsWire

Terns to Present at the UBS Global Healthcare Virtual Conference & Participate in the J.P. Morgan Biotech 2021 CEO Co...

FOSTER CITY, Calif., May 19, 2021 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-mo...

5 months ago - GlobeNewsWire

Terns to Present at the 19th Annual Virtual Needham HealthCare Conference

FOSTER CITY, Calif., April 07, 2021 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-...

6 months ago - GlobeNewsWire

Terns Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update

-Terns ended 4Q 2020 with $75 million in cash and cash equivalents and completed an upsized initial public offering in February 2021, raising approximately $147 million in gross proceeds to support oper...

6 months ago - GlobeNewsWire

The Promises Behind Terns' Multi-Pronged Pipeline

This pharma may be a newcomer to the stock market, but it has several innovative drugs in development for a common condition with no current treatments approved.

Other symbols:GILDICPTMDGLNVSPFE
6 months ago - The Motley Fool

Terns Announces Initiation of Dosing in Phase 1 Clinical Trial of TERN-501, its THR-Beta Agonist in Development for t...

-TERN-501 is designed to have high metabolic stability, enhanced liver distribution and high selectivity for THR- β-

7 months ago - GlobeNewsWire

Terns to Present at the Cowen 41st Annual Health Care Conference

FOSTER CITY, Calif., Feb. 23, 2021 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-m...

8 months ago - GlobeNewsWire

Terns Pharmaceuticals, Inc. Announces Closing of Initial Public Offering and Exercise in Full of Underwriters' Option...

FOSTER CITY, Calif., Feb. 10, 2021 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-m...

8 months ago - GlobeNewsWire

Terns Pharmaceuticals, Inc. Announces Pricing of Upsized Initial Public Offering of Common Stock Nasdaq:TERN

FOSTER CITY, Calif. -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage...

8 months ago - GlobeNewswire

Terns Pharmaceuticals, Inc. Announces Proposed Initial Public Offering of Common Stock

FOSTER CITY, Calif.--Terns Pharmaceuticals, Inc. (“Terns” or the “Company”), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule single-agent and combination therapy cand...

8 months ago - Business Wire

Terns Pharmaceuticals IPO Registration Document (S-1)

Terns Pharmaceuticals, Inc. has filed to go public with an IPO on the NASDAQ.

9 months ago - SEC

NASH biotech Terns Pharmaceuticals files for a $100 million IPO

Terns Pharmaceuticals, a Phase 2 biotech developing small molecule therapies for NASH, filed on Friday with the SEC to raise up to $100 million in an initial public offering.

9 months ago - NASDAQ

Terns Completes Enrollment in Phase 2a Clinical Trial of TERN-101 in NASH Patients

Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing a portfolio of small-molecule single-agent and combination therapy...

9 months ago - Business Wire